Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression
Sanjay Chandrasekaran, Maiko Sasaki, Christopher D. Scharer, et al.
Molecular Cancer Research (2019) Vol. 17, Iss. 12, pp. 2395-2409
Open Access | Times Cited: 50

Showing 26-50 of 50 citing articles:

Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma
Jing Yu, Xi Wu, Jinen Song, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 14
Targeting PI3Kα increases the efficacy of anti‐PD‐1 antibody in cervical cancer
Wei Jiang, Xueyan Ouyang, Chunyan Li, et al.
Immunology (2023) Vol. 170, Iss. 3, pp. 419-438
Open Access | Times Cited: 8
Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
Dan Yan
Biomedicines (2023) Vol. 11, Iss. 11, pp. 2916-2916
Open Access | Times Cited: 7
Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review
Yi Dong, L Khan, Yi Yao
Journal of the National Cancer Center (2024) Vol. 4, Iss. 4, pp. 289-298
Open Access | Times Cited: 2
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Camila Robles-Oteíza, Katherine Hastings, Jungmin Choi, et al.
The Journal of Experimental Medicine (2024) Vol. 222, Iss. 1
Closed Access | Times Cited: 2
Mechanisms of Low MHC I Expression and Strategies for Targeting MHC I with Small Molecules in Cancer Immunotherapy
S. W. Kong, Jie Zhang, Longsheng Wang, et al.
Cancer Letters (2024) Vol. 611, pp. 217432-217432
Closed Access | Times Cited: 2
Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses
Simon Heller, Sarah Glaeske, Katja Gluske, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 8, pp. 5445-5461
Open Access | Times Cited: 5
Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies
Peter E. Hall, Peter Schmid
Breast Cancer Research and Treatment (2022) Vol. 193, Iss. 1, pp. 21-35
Closed Access | Times Cited: 8
STUB1 is an intracellular checkpoint for interferon gamma sensing
Simon Ng, Shuhui Lim, Adrian Chong Nyi Sim, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Caroline Taylor, Kamai M. Patterson, Devira Friedman, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3071-3071
Open Access | Times Cited: 1
Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials
Peter E. Hall, Peter Schmid
Expert Opinion on Emerging Drugs (2021) Vol. 26, Iss. 2, pp. 131-147
Closed Access | Times Cited: 8
Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
Renzo Perales‐Linares, Nektaria Maria Leli, Hesham Mohei, et al.
Cancer Research (2023) Vol. 83, Iss. 21, pp. 3562-3576
Open Access | Times Cited: 3
Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers
Annie Wai Yeeng Chai, Pei San Yee, Sok Ching Cheong
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 5
At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma
Niels E. Wondergem, Dennis N. L. M. Nijenhuis, Jos B. Poell, et al.
Frontiers in Oral Health (2021) Vol. 2
Open Access | Times Cited: 5
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by sequential intermittent anti-PI3Kα/β/δ and anti-PD-1 treatment
Zhi Qi, Zihan Xu, Liuzhen Zhang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 4
Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell‐like properties and phosphoinositide 3‐kinase inhibitor insensitivity
Khoa Nguyen, Madison J. Keith, Stephen B. Keysar, et al.
Molecular Carcinogenesis (2022) Vol. 61, Iss. 7, pp. 664-676
Open Access | Times Cited: 3
It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC Patients
Dan Yan
(2023)
Open Access | Times Cited: 1
Impact of PI3K pathway alterations on response to immune checkpoint inhibitors in HPV-negative head and neck squamous cell carcinoma
Jong Chul Park, Nandini Pal Basak, Mateo Useche, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors
Cecilia Pesini, Laura Artal, J. Bernal, et al.
OncoImmunology (2024) Vol. 13, Iss. 1
Open Access
Patient-derived Organoids as a Tool for Advancing Precision Immuno-oncology
Xin Yi Than, Tiffany T. Ong, Edward Kai‐Hua Chow
(2024) Vol. 01
Closed Access
The membrane-associated ubiquitin ligase MARCHF8 promotes cancer immune evasion by degrading MHC class I proteins
M. I. Khalil, Jie Wang, Canchai Yang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Flow Cytometry Analysis to Detect Lapatinib-Induced Modulation of Constitutive and IFN-γ-Induced HLA Class I Expression in HER2-Positive Breast Cancer Cells
Louisa L. Wiede, Sheila Drover
Methods in molecular biology (2022), pp. 135-145
Closed Access | Times Cited: 2
STUB1 is an intracellular checkpoint for interferon gamma sensing
Simon Ng, Shuhui Lim, Adrian Chong Nyi Sim, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 2
Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management
Alessia Filippone, Deborah Mannino, Giovanna Casili, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15693-15693
Open Access | Times Cited: 1
Data from A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy
Fushun Fan, Pei Liu, Rudi Bao, et al.
(2023)
Open Access
Previous Page - Page 2

Scroll to top